Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3931) 3931
Book Review (308) 308
Publication (151) 151
Newsletter (73) 73
Book Chapter (9) 9
Magazine Article (7) 7
Conference Proceeding (5) 5
Newspaper Article (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3630) 3630
humans (3094) 3094
daunorubicin - administration & dosage (2350) 2350
male (1958) 1958
female (1872) 1872
antineoplastic combined chemotherapy protocols - therapeutic use (1533) 1533
cytarabine - administration & dosage (1503) 1503
adult (1357) 1357
middle aged (1311) 1311
oncology (1030) 1030
daunorubicin (996) 996
adolescent (993) 993
leukemia, myeloid, acute - drug therapy (907) 907
aged (888) 888
hematology (877) 877
animals (866) 866
remission induction (791) 791
vincristine - administration & dosage (662) 662
child (657) 657
chemotherapy (643) 643
daunorubicin - therapeutic use (567) 567
cancer (508) 508
treatment outcome (495) 495
child, preschool (480) 480
daunorubicin - adverse effects (472) 472
antineoplastic combined chemotherapy protocols - adverse effects (454) 454
mice (434) 434
prednisone - administration & dosage (409) 409
acute disease (401) 401
prognosis (389) 389
cyclophosphamide - administration & dosage (371) 371
pharmacology & pharmacy (370) 370
doxorubicin (367) 367
daunorubicin - pharmacology (363) 363
methotrexate - administration & dosage (362) 362
abridged index medicus (361) 361
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (361) 361
antineoplastic combined chemotherapy protocols - administration & dosage (358) 358
antibiotics, antineoplastic - administration & dosage (348) 348
time factors (347) 347
daunorubicin - analogs & derivatives (344) 344
drug administration schedule (342) 342
doxorubicin - administration & dosage (337) 337
anthracyclines (336) 336
asparaginase - administration & dosage (335) 335
thioguanine - administration & dosage (329) 329
etoposide - administration & dosage (328) 328
leukemia (321) 321
mercaptopurine - administration & dosage (312) 312
acute myelogenous leukemia (310) 310
infant (310) 310
dose-response relationship, drug (293) 293
disease-free survival (286) 286
therapy (286) 286
antineoplastic agents - administration & dosage (284) 284
leukemia, myeloid - drug therapy (281) 281
drug therapy, combination (277) 277
leukemia, myeloid, acute - mortality (276) 276
prednisolone - administration & dosage (275) 275
acute myeloid leukemia (274) 274
combined modality therapy (271) 271
rats (270) 270
acute myeloid-leukemia (262) 262
survival rate (261) 261
cytarabine - therapeutic use (245) 245
cytarabine - adverse effects (233) 233
cytarabine (229) 229
leukemia - drug therapy (229) 229
follow-up studies (227) 227
survival analysis (216) 216
mitoxantrone - administration & dosage (214) 214
idarubicin - administration & dosage (211) 211
liposomes (201) 201
recurrence (201) 201
aged, 80 and over (197) 197
retrospective studies (188) 188
idarubicin (184) 184
daunorubicin - toxicity (183) 183
daunorubicin - pharmacokinetics (181) 181
antineoplastic agents - therapeutic use (179) 179
research (178) 178
pediatrics (173) 173
leukemia, myeloid, acute - pathology (169) 169
clinical trials as topic (165) 165
aml (160) 160
leukemia, lymphoid - drug therapy (160) 160
children (159) 159
bone marrow transplantation (158) 158
young adult (158) 158
age factors (157) 157
cell line, tumor (157) 157
apoptosis (156) 156
daunorubicin - metabolism (155) 155
cells (153) 153
cytosine-arabinoside (149) 149
adriamycin (148) 148
antibiotics, antineoplastic - adverse effects (146) 146
drug resistance (145) 145
prospective studies (144) 144
medicine & public health (143) 143
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3473) 3473
Japanese (169) 169
Russian (114) 114
German (69) 69
French (47) 47
Polish (40) 40
Spanish (35) 35
Chinese (33) 33
Italian (15) 15
Czech (7) 7
Danish (4) 4
Bulgarian (2) 2
Dutch (2) 2
Hebrew (2) 2
Hungarian (2) 2
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)
by Rytting, Michael E and Thomas, Deborah A and O'Brien, Susan M and Ravandi‐Kashani, Farhad and Jabbour, Elias J and Franklin, Anna R and Kadia, Tapan M and Pemmaraju, Naveen and Daver, Naval G and Ferrajoli, Alessandra and Garcia‐Manero, Guillermo and Konopleva, Marina Y and Cortes, Jorge E and Borthakur, Gautham and Garris, Rebecca and Cardenas‐Turanzas, Maria and Schroeder, Kurt and Jorgensen, Jeffrey L and Kornblau, Steven M and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 12/2014, Volume 120, Issue 23, pp. 3660 - 3668
Retrospective analysis indicates that pediatric‐based therapy for acute lymphoblastic leukemia is superior to adult‐type therapy. This single institution... 
augmented Berlin‐Frankfurt‐Münster | pediatric‐based therapy | Philadelphia chromosome‐negative ALL | acute lymphoblastic leukemia | pediatric‐based regimens | Augmented Berlin-Frankfurt-Munster | Pediatric-based regimens | Acute lymphoblastic leukemia | Pediatric-based therapy | Philadelphia chromosome-negative ALL | ASPARAGINASE | pediatric-based therapy | pediatric-based regimens | PROGNOSTIC-FACTORS | PROTOCOLS | ACUTE LYMPHOCYTIC-LEUKEMIA | augmented Berlin-Frankfurt-Munster | RISK | INDUCTION | CANCER GROUP | CHILDHOOD | CHILDRENS ONCOLOGY GROUP | ONCOLOGY | MINIMAL RESIDUAL DISEASE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Induction Chemotherapy | Male | Consolidation Chemotherapy | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Female | Maintenance Chemotherapy | Daunorubicin - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Cohort Studies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
by Cortes, Jorge E and Goldberg, Stuart L and Feldman, Eric J and Rizzeri, David A and Hogge, Donna E and Larson, Melissa and Pigneux, Arnaud and Recher, Christian and Schiller, Gary and Warzocha, Krzysztof and Kantarjian, Hagop and Louie, Arthur C and Kolitz, Jonathan E
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
CPX‐351, a liposome‐encapsulated fixed‐molar‐ratio formulation of cytarabine and daunorubicin, exploits molar ratio–dependent drug‐drug synergy to enhance... 
Phase II | Chemotherapy Intervention | Acute Myeloid Leukemia | First Relapse | Acute myeloid leukemia | First relapse | Chemotherapy intervention | EFFICACY | ONCOLOGY | CYTARABINEDAUNORUBICIN | ACUTE MYELOID-LEUKEMIA | MOLAR RATIO | FORMULATION | Recurrence | Mitoxantrone - administration & dosage | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Aminoglycosides - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Daunorubicin - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Amsacrine - administration & dosage | Vidarabine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Cladribine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Injections | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Vidarabine - administration & dosage | Liposomes | Salvage Therapy - methods | Chemotherapy | Usage | Health aspects | Patient outcomes | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
by Löwenberg, Bob and Ossenkoppele, Gert J and van Putten, Wim and Schouten, Harry C and Graux, Carlos and Ferrant, Augustin and Sonneveld, Pieter and Maertens, Johan and Jongen-Lavrencic, Mojca and von Lilienfeld-Toal, Marie and Biemond, Bart J and Vellenga, Edo and Kooy, Marinus van Marwijk and Verdonck, Leo F and Beck, Joachim and Döhner, Hartmut and Gratwohl, Alois and Pabst, Thomas and Verhoef, Gregor and Swiss Grp Clinical Canc Res SAKK C and Dutch-Belgian Cooperative Trial Gr and German AML Study Grp AMLSG and Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and German AML Study Group (AMLSG) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1235 - 1248
Patients with acute myeloid leukemia (AML) who were more than 60 years of age received treatment to induce a complete remission that consisted of cytarabine... 
TRIAL | MEDICINE, GENERAL & INTERNAL | COOPERATIVE-GROUP | COLONY-STIMULATING FACTOR | SOUTHWEST-ONCOLOGY-GROUP | REMISSION-INDUCTION CHEMOTHERAPY | RANDOMIZED PHASE-III | EUROPEAN ORGANIZATION | RISK MYELODYSPLASTIC SYNDROME | CYTARABINE | ELDERLY-PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Antibodies, Monoclonal, Humanized | Leukemia, Myelomonocytic, Acute - therapy | Aminoglycosides - administration & dosage | Aged, 80 and over | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Aged | Infusions, Intravenous | Leukemia, Myelomonocytic, Acute - mortality | Aged patients | Usage | Dosage and administration | Daunorubicin | Health aspects | Medical treatment | Leukemia | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
by Powell, Bayard L and Moser, Barry and Stock, Wendy and Gallagher, Robert E and Willman, Cheryl L and Stone, Richard M and Rowe, Jacob M and Coutre, Steven and Feusner, James H and Gregory, John and Couban, Stephen and Appelbaum, Frederick R and Tallman, Martin S and Larson, Richard A
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 19, pp. 3751 - 3757
Arsenic trioxide (As2O3) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for... 
CONSOLIDATION | MULTICENTER | THERAPY | RISK-ADAPTED TREATMENT | EFFICACY | ANTHRACYCLINE MONOCHEMOTHERAPY | TOXICITY | TRANS-RETINOIC ACID | HEMATOLOGY | PETHEMA GROUP | CHEMOTHERAPY | Tretinoin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Mercaptopurine - administration & dosage | Male | Treatment Outcome | North America | Cytarabine - administration & dosage | Young Adult | Disease-Free Survival | Arsenicals - administration & dosage | Adolescent | Leukemia, Promyelocytic, Acute - mortality | Survival Analysis | Adult | Female | Methotrexate - administration & dosage | Aged | Daunorubicin - administration & dosage | Oxides - administration & dosage | Leukemia, Promyelocytic, Acute - drug therapy | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation
by Zhao, Peiqi and Wang, Huaqing and Wang, Xianhuo and Wang, Hanjie and Yu, Man and Liao, Zhenyu and Zhang, Fei and Zhang, Haichang and Ji, Wei and Wu, Bing and Han, Jinghua and Chang, Jin and Niu, Ruifang
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 06/2012, Volume 81, Issue 2, pp. 248 - 256
Schematic illustration of drug-loaded folic acid targeted nanoparticles of mixed lipid-shell and PLGA core (FLPNPs). A functional drug carrier comprised of... 
Drug delivery | PLGA | Nanoparticle | Paclitaxel | GYNECOLOGIC-ONCOLOGY-GROUP | BIODEGRADABLE MICROSPHERES | DRUG-DELIVERY | CONTROLLED-RELEASE | PHASE-II | LIPOSOMAL DAUNORUBICIN | CANCER | RECURRENT | ENDOTHELIAL-CELLS | METASTATIC NASOPHARYNGEAL CARCINOMA | PHARMACOLOGY & PHARMACY | Polymers - administration & dosage | Nanoparticles - chemistry | Humans | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Lipids - chemistry | Female | Paclitaxel - administration & dosage | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Lactic Acid - chemistry | Drug Compounding - methods | Chitosan - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Lipids - administration & dosage | Mice, SCID | Chemistry, Pharmaceutical | Polyethylene Glycols - administration & dosage | Particle Size | Animals | Chitosan - chemistry | Polyglycolic Acid - chemistry | Cell Line, Tumor | Folic Acid - metabolism | Polymers - chemistry | Mice | Nanoparticles - administration & dosage | HeLa Cells | Drug Delivery Systems - methods | Drugs | Phosphates | Drug delivery systems | Leukemia | Liquid chromatography | Permeability | Chromatography | Folic acid | Vehicles | Nanoparticles | Lysine | Fluorescein | Dimethyl sulfoxide | Lymphomas | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95
by Hinze, L and Möricke, A and Zimmermann, M and Junk, S and Cario, G and Dagdan, E and Kratz, C.P and Conter, V and Schrappe, M and Stanulla, M
Leukemia, ISSN 0887-6924, 08/2017, Volume 31, Issue 8, pp. 1840 - 1842
ONCOLOGY | HEMATOLOGY | CHILDREN | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Mercaptopurine - administration & dosage | Child, Preschool | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Ikaros Transcription Factor - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Gene Deletion | Adolescent | Vincristine - administration & dosage | Methotrexate - administration & dosage | Child | Daunorubicin - administration & dosage | Dexamethasone | Acute lymphatic leukemia | Children | Lymphatic leukemia | Vincristine | Leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adolescents with acute lymphoblastic leukaemia: Outcome on UK National Paediatric (ALL97) and adult (UKALLXII/E2993) trials
by Ramanujachar, Ramya and Richards, Sue and Hann, Ian and Goldstone, Anthony and Mitchell, Christopher and Vora, Ajay and Rowe, Jacob and Webb, David
Pediatric Blood and Cancer, ISSN 1545-5009, 03/2007, Volume 48, Issue 3, pp. 254 - 261
Background. Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL. Their... 
Treatment outcome | Acute lymphoblastic leukemia | Survival | Adolescent | Young adult | YOUNG-ADULTS | MAINTENANCE CHEMOTHERAPY | RANDOMIZED-TRIALS | PROTOCOLS | survival | young adult | INDUCTION | treatment outcome | CHILDHOOD | CONSOLIDATION | THERAPY | ONCOLOGY | acute lymphoblastic leukemia | TERM FOLLOW-UP | adolescent | PEDIATRICS | CHILDRENS CANCER GROUP | HEMATOLOGY | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Prognosis | Age Factors | Humans | Male | Transplantation, Autologous | Transplantation, Homologous | Patient Selection | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Bone Marrow Transplantation | Vincristine - administration & dosage | Female | Daunorubicin - administration & dosage | Randomized Controlled Trials as Topic - statistics & numerical data | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Methotrexate - administration & dosage | Research Design | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Is a New Protocol for Acute Lymphoblastic Leukemia Research or Standard Therapy?
by Dekking, SAS and van der Graaf, R and de Vries, Martine and Bierings, MB and van Delden, JJM and Kodish, Eric and Lantos, John
Pediatrics, ISSN 0031-4005, 2015, Volume 136, Issue 3, pp. 566 - 570
In the United States, doctors generally develop new cancer chemotherapy for children by testing innovative chemotherapy protocols against existing protocols in... 
PEDIATRICS | Leucovorin - administration & dosage | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Therapeutic Human Experimentation - ethics | Dexamethasone - administration & dosage | Risk Assessment | United States | Humans | Clinical Protocols | Mercaptopurine - administration & dosage | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Netherlands | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Evidence-Based Medicine - ethics | Vincristine - administration & dosage | Methotrexate - administration & dosage | Child | Daunorubicin - administration & dosage | Medical protocols | Care and treatment | Chemotherapy | Usage | Analysis | Research ethics | Acute lymphocytic leukemia | Cancer | Clinical trials | Pediatrics | Leukemia | Children & youth | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy
by Xiao, Haihua and Li, Wenliang and Qi, Ruogu and Yan, Lesan and Wang, Rui and Liu, Shi and Zheng, Yonghui and Xie, Zhigang and Huang, Yubin and Jing, Xiabin
Journal of Controlled Release, ISSN 0168-3659, 11/2012, Volume 163, Issue 3, pp. 304 - 314
An oxaliplatin pro-drug (Oxa(IV)–COOH) with an axial carboxyl group was synthesized and conjugated to biodegradable polymers with pendant hydroxyl groups to... 
Drug delivery | Daunorubicin | Oxaliplatin | Combination chemotherapy | Polymer conjugates | ENDOMETRIAL CARCINOMA | PHASE-III | DOXORUBICIN | PLATINUM(IV) COMPLEXES | OVARIAN-CANCER | CHEMISTRY, MULTIDISCIPLINARY | CISPLATIN | REDUCTION | GLUTATHIONE | PHARMACOLOGY & PHARMACY | ANTICANCER DRUGS | DAUNORUBICIN CARDIOTOXICITY | Prodrugs - administration & dosage | Cell Survival - drug effects | Polymers - administration & dosage | Organoplatinum Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Micelles | Cell Line, Tumor | Drug Carriers - administration & dosage | Antineoplastic Agents - administration & dosage | Daunorubicin - administration & dosage | Drugs | Care and treatment | Drug delivery systems | Oxalic acid | Drug therapy, Combination | Polymer industry | Polymers | Cancer | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Long-term results of the risk-adapted treatment for childhood B-cell acute lymphoblastic leukemia: Report from the Japan association of childhood leukemia study ALL-97 trial
by Horibe, Keizo and Yumura-Yagi, Keiko and Kudoh, Tooru and Nishimura, Shinichiro and Oda, Megumi and Yoshida, Makoto and Komada, Yoshihiro and Hara, Junichi and Tawa, Akio and Usami, Ikuya and Tanizawa, Akihiko and Kato, Koji and Kobayashi, Ryoji and Matsuo, Keitaro and Hori, Hiroki and Japan Assoc Childhood Leukemia Stu and Japan Association of Childhood Leukemia Study (JACLS), Japan
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2017, Volume 39, Issue 2, pp. 81 - 89
Purpose: This study was conducted as the first clinical trial by Japan Association of Childhood Leukemia Study to improve the outcome of B-cell acute... 
clinical trial | childhood | acute lymphoblastic leukemia | STANDARD-RISK | DOXORUBICIN | CARDIOTOXICITY | CANCER | CHILDRENS ONCOLOGY GROUP | THERAPY | ONCOLOGY | ANTHRACYCLINE | CONSECUTIVE TRIALS | PEDIATRICS | BFM STUDY-GROUP | CRANIAL IRRADIATION | HEMATOLOGY | Japan - epidemiology | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Risk | Consolidation Chemotherapy | Hydrocortisone - administration & dosage | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Doxorubicin - analogs & derivatives | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Daunorubicin - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Survival Rate | Treatment Outcome | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - radiotherapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Asparaginase - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
by Lancet, Jeffrey E and Cortes, Jorge E and Hogge, Donna E and Tallman, Martin S and Kovacsovics, Tibor J and Damon, Lloyd E and Komrokji, Rami and Solomon, Scott R and Kolitz, Jonathan E and Cooper, Maureen and Yeager, Andrew M and Louie, Arthur C and Feldman, Eric J
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
CPX-351 is a liposomal formulation of cytarabine: daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly... 
SOUTHWEST-ONCOLOGY-GROUP | COMPLETE REMISSION | CYTARABINEDAUNORUBICIN | ACUTE MYELOID-LEUKEMIA | INDUCTION | DAUNORUBICIN | FORMULATION | HEMATOLOGY | CYTOGENETICS | CHEMOTHERAPY | AGE | Daunorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Liposomes | Daunorubicin - administration & dosage | Index Medicus | Abridged Index Medicus | 33 | 8 | Clinical Trials and Observations | 29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
by Grimwade, David and Walker, Helen and Harrison, Georgina and Oliver, Fiona and Chatters, Stephen and Harrison, Christine J and Wheatley, Keith and Burnett, Alan K and Goldstone, Anthony H and Med Res Council Adult Leukae and Medical Research Council Adult Leukemia Working Party
Blood, ISSN 0006-4971, 09/2001, Volume 98, Issue 5, pp. 1312 - 1320
Acute myeloid leukemia (AML) in older adults carries a poor prognosis, and the optimum treatment remains to be determined. In younger patients, treatment... 
P53 MUTATIONS | THERAPY | SOUTHWEST-ONCOLOGY-GROUP | BONE-MARROW-TRANSPLANTATION | MICROSATELLITE INSTABILITY | MYELOGENOUS LEUKEMIA | HEMATOLOGY | ELDERLY-PATIENTS | ACUTE MYELOBLASTIC-LEUKEMIA | ACUTE PROMYELOCYTIC LEUKEMIA | CLINICAL-SIGNIFICANCE | Recombinant Proteins - therapeutic use | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Age Factors | Follow-Up Studies | Humans | Leukemia, Myeloid - genetics | Middle Aged | Male | Life Tables | Leukemia, Myeloid - classification | Karyotyping | Vincristine - administration & dosage | Adult | Female | Leukemia, Myeloid - mortality | Daunorubicin - administration & dosage | Lenograstim | Prednisone - administration & dosage | Drug Administration Schedule | Interferon-alpha - therapeutic use | Etoposide - administration & dosage | Treatment Outcome | Granulocyte Colony-Stimulating Factor - therapeutic use | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Leukemia, Myeloid - drug therapy | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chromosome Aberrations | Survival Analysis | Aged | United Kingdom - epidemiology | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96
by Josep-María Ribera and Albert Oriol and Miguel-Angel Sanz and Mar Tormo and Pascual Fernández-Abellán and Eloy del Potro and Eugenia Abella and Javier Bueno and Ricardo Parody and Pilar Bastida and Carlos Grande and Inmaculada Heras and Concepción Bethencourt and Evarist Feliu and Juan-José Ortega
Journal of Clinical Oncology, ISSN 0732-183X, 04/2008, Volume 26, Issue 11, pp. 1843 - 1849
Purpose Retrospective studies have shown that adolescents and young adults with acute lymphoblastic leukemia (ALL) treated with pediatric protocols have better... 
TRIAL | INTENSIVE CHEMOTHERAPY | THERAPY | ONCOLOGY | POSTREMISSION TREATMENT | STEM-CELL TRANSPLANTATION | CHILDREN | Cyclophosphamide - administration & dosage | Prognosis | Age Factors | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Infection - chemically induced | Hydrocortisone - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Female | Child | Daunorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial
by Mattano, Leonard A, Prof and Devidas, Meenakshi, PhD and Nachman, James B, Prof and Sather, Harland N, PhD and Hunger, Stephen P, Prof and Steinherz, Peter G, Prof and Gaynon, Paul S, Prof and Seibel, Nita L, MD and Children's Oncology Grp and Children's Oncology Group
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 906 - 915
Summary Background Acute lymphoblastic leukaemia (ALL) is curable in more than 80% of children and adolescents who exhibit high-risk features. However,... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | THERAPY | ONCOLOGY | COMPLICATION | ADOLESCENTS | GLUCOCORTICOID-INDUCED OSTEONECROSIS | CHILDRENS CANCER GROUP | MODEL | FAT-CELL ENLARGEMENT | AVASCULAR NECROSIS | CHEMOTHERAPY | Osteonecrosis - epidemiology | Humans | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Incidence | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Child | Daunorubicin - administration & dosage | Osteonecrosis - diagnosis | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Survival Rate | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Sex Factors | Sex Distribution | Methotrexate - administration & dosage | Osteonecrosis - chemically induced | Osteonecrosis - prevention & control | Cohort Studies | Pediatrics | Hunger | Dexamethasone | Bones | Public health | Necrosis | Steroids | Index Medicus
Journal Article